Sunday, January 13, 2019 10:11:28 AM
With all due respect, your predictions have not been too accurate. I don’t mean that as a flaw, more to point out that we really don’t know what next week will bring. Finesand is kind of the opposite, wanting to analyze closely and jump in right before the actual catalyst that moves the sp. I really don’t care too much for either, I just want some concrete rational of how we are in this pickle. Trding’s explanation for why there is such skepticism by the BP and VC for this technology goes a long way to explaining the steepness of the hill we are climbing. Many have been burned investing in the next great thing and have it turn out to be worthless.
There must be some reason why the BOD, which is made up of a diverse set of very successful and smart people support Nader. We don’t know if behind the scenes if Nader is on thin ice or we just don’t know the genius of his plan?
There are many things about our history and current situation that we can be armchair quarterbacks on. A few times in the past I’ve supported Nader mostly because replacing him might be more disruptive that it is worth. I can say that if Nader was refusing stock options and buying stock with his own money, the support would be much greater. In reality, Nader alone is not the obstruction, he is easy to blame but the science will steamroll right over his shortcomings.
The nature of the past raises has been built on individual investors, it is hard to get tens of millions this way. there is a huge amount of sales pitch to get a $50k investment. In reality if we really only need $20 million, we are in good shape. With this last push funding, we have a BLA filed and a cancer drug. Keep in mind, there is some big money investors that are not going to let there investment fail just for a shortage of funds.
There must be some reason why the BOD, which is made up of a diverse set of very successful and smart people support Nader. We don’t know if behind the scenes if Nader is on thin ice or we just don’t know the genius of his plan?
There are many things about our history and current situation that we can be armchair quarterbacks on. A few times in the past I’ve supported Nader mostly because replacing him might be more disruptive that it is worth. I can say that if Nader was refusing stock options and buying stock with his own money, the support would be much greater. In reality, Nader alone is not the obstruction, he is easy to blame but the science will steamroll right over his shortcomings.
The nature of the past raises has been built on individual investors, it is hard to get tens of millions this way. there is a huge amount of sales pitch to get a $50k investment. In reality if we really only need $20 million, we are in good shape. With this last push funding, we have a BLA filed and a cancer drug. Keep in mind, there is some big money investors that are not going to let there investment fail just for a shortage of funds.
Recent CYDY News
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/22/2025 10:15:23 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/17/2025 05:15:14 AM
- December 2025 Letter to Shareholders • GlobeNewswire Inc. • 12/16/2025 01:30:00 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 12/10/2025 10:16:32 PM
- CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium • GlobeNewswire Inc. • 12/08/2025 01:30:00 PM
